Lataa...
Biosimilar Trastuzumab in Clinical Trials: Differences or Not?
In the last decade, cancer therapies have increasingly taken the form of combination treatments in which biologic agents play a crucial role. In breast cancer, the treatment strategy is adjusted to intrinsic subtypes such as human epidermal growth factor receptor-2(HER2)-positive. With the introduct...
Tallennettuna:
| Julkaisussa: | Breast Care (Basel) |
|---|---|
| Päätekijä: | |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
S. Karger GmbH
2019
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6465702/ https://ncbi.nlm.nih.gov/pubmed/31019438 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000496503 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|